Sealing problem found in some Redipens

Schering-Plough SOL Limited, which produces the PegIntron Redipen to deliver peginterferon alfa-2b to treat hepatitis C, has told the Hong Kong Department of Health about a sealing defect involving glass cartridges in the system. The product is an alternative to traditional vials and syringes. The company says the defect occurs in about three out of every 20,000 devices. Because it's found in so few devices, the company is proposing to send representatives to all doctor's offices and hospitals involved to inspect their stock of the device. The Health Department gave the plan the go-ahead and Schering-Plough has set up a hotline--3791 2987--for public enquiries. Report

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.